Exploring Deferoxamine-B for resensitization and antimicrobial resistance mitigation in drug resistant Klebsiella pneumoniae and Staphylococcus aureus: an in vitro study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253963Keywords:
Klebsiella pneumoniae, Staphylococcus aureus, AMR, MDR, XDR, ESBL, MBL, Siderophores, Deferoxamine-BAbstract
Background: The rising incidence of antimicrobial resistance (AMR) in pathogens like Klebsiella pneumoniae and Staphylococcus aureus is a major global concern. Resistance mechanisms such as extended spectrum β-lactamases (ESBLs), metallo β-lactamases (MBLs), and methicillin resistance limit treatment options. Iron-chelating siderophores like DFO-B may disrupt bacterial iron metabolism and potentially resensitize resistant strains to antibiotics.
Methods: This in vitro cross-sectional study assessed the adjunctive effect of DFO-B with selected antibiotics against clinical isolates of MDR K. pneumoniae and S. aureus. Isolates were identified, and antibiotic susceptibility was determined using disc diffusion and micro broth dilution. Synergy between DFO-B and antibiotics was evaluated by disc diffusion enhancement and MIC reduction assays.
Results: Among 100 K. pneumoniae isolates, 54% were multidrug-resistant and 46% extensively drug-resistant; 83% produced ESBLs and 70% showed MBL activity, with high resistance to third-generation cephalosporins. DFO-B alone showed no antibacterial effect and did not enhance antibiotic activity, displaying indifferent interactions and mild antagonism with imipenem in ESBL producers. Among 128 S. aureus isolates, tigecycline showed 100% susceptibility in both MSSA and MRSA, with no additional effect from DFO-B. Cefdinir and ampicillin showed higher resistance in MRSA, but their activity improved in the presence of DFO-B, with cefdinir showing a marked increase in MRSA susceptibility and ampicillin showing modest improvement.
Conclusion: DFO-B did not enhance antibiotic activity against MDR K. pneumoniae, but it showed some potential to increase susceptibility in selected S. aureus strains. These results highlight the complex role of siderophore-mediated iron chelation in AMR and the need for further research to optimize such combination therapies.
Metrics
References
Eftekhar F, Naseh Z. Extended-spectrum β-lactamase and carbapenemase production among burn and non-burn clinical isolates of Klebsiella pneumoniae. Iran J Microbiol. 2015;7(3):144-9.
Zhang Y, Wang M, Li Z, Peng Y, Yang Y, Liu X, et al. Characteristics of ESBL-positive Klebsiella pneumoniae isolated from paired children with and without diarrhea. Gut Pathog. 2025;17(1):36. DOI: https://doi.org/10.1186/s13099-025-00700-9
Li J, Shi Y, Song X, Yin X, Liu H. Mechanisms of Antimicrobial Resistance in Klebsiella: Advances in Detection Methods and Clinical Implications. Infect Drug Resist. 2025;18:1339-54. DOI: https://doi.org/10.2147/IDR.S509016
Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. DOI: https://doi.org/10.3389/fcimb.2018.00004
Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2025;18(12):711-25.
Bellotti D, Remelli M. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021;26(11):3255. DOI: https://doi.org/10.3390/molecules26113255
Van Asbeck BS, Marcelis JH, Marx JJ, Struyvenberg A, van Kats JH, Verhoef J. Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid. Eur J Clin Microbiol. 1983;2(5):426-31. DOI: https://doi.org/10.1007/BF02013899
Erinmez M, Zer Y. In vitro effects of deferoxamine on antibiotic susceptibility in Gram-negative bacteria. Adv Clin Exp Med. 2024;33(5):491-7. DOI: https://doi.org/10.17219/acem/169794
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 35th Edition. 2025.
Gokarn K, Pal RB. Activity of siderophores against drug-resistant Gram-positive and Gram-negative bacteria. Infect Drug Resist. 2018;11:61-75. DOI: https://doi.org/10.2147/IDR.S148602
Yan W, Liang J, Liu M, Hu X, Zhang H, Guo J, et al. Clinical and Antibiotic Resistance Features for Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Infections and Predictors of Poor Prognosis in Neonatal Patients. Infect Drug Resist. 2025;18:3907-18. DOI: https://doi.org/10.2147/IDR.S530585
Ali Abdel Rahim KA, Ali Mohamed AM. Prevalence of Extended Spectrum β-lactamase-Producing Klebsiella pneumoniae in Clinical Isolates. Jundishapur J Microbiol. 2014;7(11):e17114. DOI: https://doi.org/10.5812/jjm.17114
Kim CM, Shin SH. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J Korean Med Sci. 2009;24(2):289-95. DOI: https://doi.org/10.3346/jkms.2009.24.2.289
Haider MH, McHugh TD, Roulston K, Arruda LB, Sadouki Z, Riaz S. Detection of carbapenemases blaOXA48-blaKPC-blaNDM-blaVIM and extended-spectrum-β-lactamase blaOXA1-blaSHV-blaTEM genes in Gram-negative bacterial isolates from ICU burns patients. Ann Clin Microbiol Antimicrob. 2022;21(1):18. DOI: https://doi.org/10.1186/s12941-022-00519-1
Temel A, Aksoyalp ZŞ. A Preliminary Study on the Effect of Deferoxamine on the Disruption of Bacterial Biofilms and Antimicrobial Resistance. Turk J Pharm Sci. 2024;21(4):267-73.
Hartzen SH, Frimodt-Møller N, Frølund Thomsen V. The antibacterial activity of a siderophore. 1. In vitro activity of deferoxamine alone and in combination with ascorbic acid on Staphylococcus aureus. APMIS. 1989;97(5):419-24. DOI: https://doi.org/10.1111/j.1699-0463.1989.tb00809.x
Downloads
Published
How to Cite
Issue
Section
